macugen
pharmaswiss ceska republika s.r.o - pegaptanib - wet macular degeneration - oftalmoloģiskie līdzekļi - macugen ir indicēts neovaskulārai (mitrai) ar vecumu saistītā makulas deģenerācijai (amd).
mac-cao superfood blend (2016.) pulveris
organic d.o.o. - pulveris
yesafili
viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - oftalmoloģiskie līdzekļi - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.
byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmoloģiskie līdzekļi - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmoloģiskie līdzekļi - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
vabysmo
roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmoloģiskie līdzekļi - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmoloģiskie līdzekļi - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
aclasta
sandoz pharmaceuticals d.d. - zoledronic acid - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - zāles kaulu slimību ārstēšanai - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture, including those with a recent low-trauma hip fracture. attieksmi pret osteoporozi, kas saistītas ar ilgtermiņa sistēmisko glikokortikoīdu terapija sievietēm pēc menopauzes un vīriešiem paaugstināts risks lūzums. Ārstēšana paget ir slimības ar kaulu.
akynzeo
helsinn birex pharmaceuticals ltd - netupitant, palonosetron hidrohlorīds - vomiting; neoplasms; nausea; cancer - pretvemšanas un antinauseants, - akynzeo ir norādīts pieaugušajiem:novēršanai akūta un aizkavēta nelabums un vemšana, kas saistīta ar ļoti emetogenic cisplatin, pamatojoties vēža ķīmijterapija. profilakse-akūta un aizkavēta nelabums un vemšana, kas saistīta ar mēreni emetogenic vēža ķīmijterapija.
aloxi
helsinn birex pharmaceuticals ltd. - palonosetron hydrochloride - vomiting; cancer - pretvemšanas un antinauseants, , serotonīns (5ht3) antagonisti - aloxi ir norādīts pieaugušajiem:novērst akūtas slikta dūša un vemšana, kas saistīta ar ļoti emetogenic vēža ķīmijterapija,profilakses, slikta dūša un vemšana, kas saistīta ar mēreni emetogenic vēža ķīmijterapija. aloxi ir norādīts pediatrijas pacientiem no 1 mēneša vecuma un vecākiem:novērst akūtas slikta dūša un vemšana, kas saistīta ar ļoti emetogenic vēža ķīmijterapija un novēršanu, slikta dūša un vemšana, kas saistīta ar mēreni emetogenic vēža ķīmijterapija.